Tabish, Tanveer A, Pranjol, Md Zahidul I, Whatmore, Jacqueline L and Zhang, Shaowei (2020) Status and future directions of anti-metastatic cancer nanomedicines for the inhibition of cathepsin L. Frontiers in Nanotechnology, 2 (a1). pp. 1-10. ISSN 2673-3013

PDF - Published Version Available under License Creative Commons Attribution. Download (710kB)

Abstract

Angiogenesis, tissue invasion and metastasis in the tumour microenvironment are all critical hallmarks of cancer. Upregulation of cathepsin L plays an important role in angiogenesis and metastasis through its ability to degrade the extracellular matrix, facilitating tissue remodeling and tumour cell invasion. Thus, cathepsin L is a potential therapeutic target for anticancer nanomedicine, with its inhibition emerging as an innovative and potentially promising therapeutic intervention for the development of anti-invasion and anti-metastatic enzyme therapies. Nanotechnology-based platforms have been extensively tested in the anti-cancer nanomedicine field with effective anti-tumour efficacy. These nanodrugs can suppress tumour cell proliferation, thereby reducing tumour growth. Recently, nanomedicinal approaches have also emerged as effective anti-metastatic strategies, including the use of graphene oxide and gold nanoparticles. With a focus on recent advances in developing nanotechnology to inhibit cathepsin L, this review provides an in-depth examination of this stimulating field in the context of tumour microenvironments. Innovative anti-metastatic agents may lead to new options for the treatment of cancers.

Item Type:	Article
Schools and Departments:	School of Life Sciences > Biochemistry
SWORD Depositor:	Mx Elements Account
Depositing User:	Mx Elements Account
Date Deposited:	19 May 2020 10:02
Last Modified:	21 May 2020 09:45
URI:	http://sro.sussex.ac.uk/id/eprint/91308

View download statistics for this item

📧 Request an update